AbbVie (ABBV) Enterprise Value (2012 - 2026)
AbbVie (ABBV) posted quarterly Enterprise Value of -$9.3 billion for Q1 2026, down 82.06% year-over-year from -$52.1 billion in Q1 2025, and down 79.23% quarter-over-quarter from -$5.2 billion in Q4 2025.
AbbVie (ABBV) Enterprise Value (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Enterprise Value for 15 consecutive years, with -$9.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 82.06% year-over-year to -$9.3 billion; the TTM figure through Mar 2026 stood at -$9.3 billion (down 82.06% YoY), while the FY2025 annual figure was -$5.2 billion, up 5.46% from the prior year.
- Enterprise Value eased to -$9.3 billion in Q1 2026 per ABBV's latest filing, from -$5.2 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$5.1 billion in Q1 2025 and bottomed at -$18.0 billion in Q1 2024.
- Historically, Enterprise Value has averaged -$9.2 billion across 5 years, with a median of -$8.7 billion in 2023.
- Annual changes were most pronounced in 2024 — Enterprise Value tumbled 169.37% — and 2025, when it surged 71.52%.
- AbbVie's Enterprise Value stood at -$9.2 billion in 2022, then plunged by 38.96% to -$12.8 billion in 2023, then surged by 56.84% to -$5.5 billion in 2024, then climbed by 5.46% to -$5.2 billion in 2025, then plunged by 79.23% to -$9.3 billion in 2026.
- Business Quant data shows ABBV's Enterprise Value at -$9.3 billion in Q1 2026, -$5.2 billion in Q4 2025, and -$5.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.52 Bn |
| Mar 31, 2026 | -9.35 Bn |
| Dec 31, 2025 | -5.22 Bn |
| Sep 30, 2025 | -5.63 Bn |
| Jun 30, 2025 | -6.42 Bn |
| Mar 31, 2025 | -5.13 Bn |
| Dec 31, 2024 | -5.52 Bn |
| Sep 30, 2024 | -7.25 Bn |
| Jun 30, 2024 | -13.11 Bn |
| Mar 31, 2024 | -18.03 Bn |
| Dec 31, 2023 | -12.78 Bn |
| Sep 30, 2023 | -13.26 Bn |
| Jun 30, 2023 | -8.73 Bn |
| Mar 31, 2023 | -6.69 Bn |
| Dec 31, 2022 | -9.20 Bn |
| Sep 30, 2022 | -11.85 Bn |
| Jun 30, 2022 | -9.93 Bn |
| Mar 31, 2022 | -7.54 Bn |
| Dec 31, 2021 | -9.80 Bn |
| Sep 30, 2021 | -12.22 Bn |